Paper381925
Marrow transplantation for acute nonlymphoblastic leukemia in first remission.
Thomas ED and 11 others. N Engl J Med, 1979. Cited by 689 papers, by iCite.
Cite this record
ConductScience Library. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. Papers, record 381925. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/381925
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Marrow Transplantation | Major topic |
| Leukemia | Major topic |
| Acute Disease | |
| Adolescent | |
| Adult | |
| Child | |
| Humans | |
| Leukemia, Monocytic, Acute | |
| Leukemia, Myeloid | |
| Leukemia, Myeloid, Acute | |
| Middle Aged | |
| Remission, Spontaneous | |
| Time Factors | |
| Transplantation, Homologous |
Source PubMed
Cited by101
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 689 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41462915 | Allogeneic Hematopoietic Stem Cell Transplantation as a Therapeutic Approach for Hereditary Diseases. | Biomedicines | 2025 | https://conductscience.org/library/papers/41462915 | PubMed |
| 41331040 | The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantation. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/41331040 | PubMed |
| 40207714 | Reduced incidence of relapse and graft-versus-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation. | Haematologica | 2025 | https://conductscience.org/library/papers/40207714 | PubMed |
| 40100591 | Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective. | Methods Mol Biol | 2025 | https://conductscience.org/library/papers/40100591 | PubMed |
| 39147891 | Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/39147891 | PubMed |
| 38909530 | Cancer treatments: Past, present, and future. | Cancer Genet | 2024 | https://conductscience.org/library/papers/38909530 | PubMed |
| 38571944 | Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect. | Front Immunol | 2024 | https://conductscience.org/library/papers/38571944 | PubMed |
| 38181752 | Hallmarks of stemness in mammalian tissues. | Cell Stem Cell | 2024 | https://conductscience.org/library/papers/38181752 | PubMed |
| 38098489 | Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development. | Front Immunol | 2023 | https://conductscience.org/library/papers/38098489 | PubMed |
| 37627165 | Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37627165 | PubMed |
| 36698790 | Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders. | Front Genome Ed | 2022 | https://conductscience.org/library/papers/36698790 | PubMed |
| 36341432 | Antibody based conditioning for allogeneic hematopoietic stem cell transplantation. | Front Immunol | 2022 | https://conductscience.org/library/papers/36341432 | PubMed |
| 35926108 | Single-cell genomics in AML: extending the frontiers of AML research. | Blood | 2023 | https://conductscience.org/library/papers/35926108 | PubMed |
| 35318487 | Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies. | Strahlenther Onkol | 2022 | https://conductscience.org/library/papers/35318487 | PubMed |
| 35242706 | Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse. | Front Oncol | 2022 | https://conductscience.org/library/papers/35242706 | PubMed |
| 35053386 | Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing. | Cells | 2022 | https://conductscience.org/library/papers/35053386 | PubMed |
| 34864823 | Differentiation therapy for myeloid malignancies: beyond cytotoxicity. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/34864823 | PubMed |
| 34831068 | From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives. | Cells | 2021 | https://conductscience.org/library/papers/34831068 | PubMed |
| 34750175 | Hematopoietic Stem Cells and Regeneration. | Cold Spring Harb Perspect Biol | 2022 | https://conductscience.org/library/papers/34750175 | PubMed |
| 34595407 | Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation. | Clin Hematol Int | 2019 | https://conductscience.org/library/papers/34595407 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/381925
GET https://conductscience.org/api/papers/v1/381925/cited_by?page=2